Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib
DOI:
https://doi.org/10.2340/actadv.v104.18452Keywords:
atopic dermatitis, itch, Janus kinase inhibitor, skin clearance, treat-to-target, upadacitinibAbstract
A treat-to-target approach was recently developed to guide systemic treatment for adults with atopic dermatitis (AD). Recommendations outlined criteria for a 3-month initial acceptable treatment target and a 6-month optimal target, evaluated using global assessment of patient-reported disease severity, as well as Eczema Area and Severity Index, itch assessed on an 11-point numerical rating scale, Dermatology Life Quality Index, or Patient-Oriented Eczema Measure. Achievement of these targets with once-daily upadacitinib (15 mg and 30 mg) monotherapy was evaluated using integrated adult data from the Measure Up 1 and 2 phase 3 studies. Among the 852 patients treated with upadacitinib 15 mg or 30 mg, the 3-month initial acceptable target was achieved by >80%, >78%, and ≥87% of patients, and the 6-month optimal target was achieved by ≥53%, >61%, and >73% of patients at weeks 2, 16, and 52, respectively. Achievement of all 6 individual criteria for each of the target goals also increased over time. These findings suggest that upadacitinib 15 mg and 30 mg may help improve standards of care in patients with moderate-to-severe AD by achieving 6-month target goals at 16 weeks and as early as 2 weeks for most patients.
Downloads
References
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396: 345-360.
https://doi.org/10.1016/S0140-6736(20)31286-1 DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
Elsawi R, Dainty K, Smith Begolka W, Barta K, Butler L, Capozza K, et al. The multidimensional burden of atopic dermatitis among adults: results from a large national survey. JAMA Dermatol 2022; 158: 887-892.
https://doi.org/10.1001/jamadermatol.2022.1906 DOI: https://doi.org/10.1001/jamadermatol.2022.1906
Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 2022; 21: 21-40.
https://doi.org/10.1038/s41573-021-00266-6 DOI: https://doi.org/10.1038/s41573-021-00266-6
Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol 2017; 140: 633-643.
https://doi.org/10.1016/j.jaci.2017.07.006 DOI: https://doi.org/10.1016/j.jaci.2017.07.006
de Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402.
https://doi.org/10.2340/00015555-3751 DOI: https://doi.org/10.2340/00015555-3751
Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2018; 2: 23.
https://doi.org/10.1186/s41927-018-0031-x DOI: https://doi.org/10.1186/s41927-018-0031-x
Voss J, Graff C, Schwartz A, Hyland D, Argiriadi M, Camp HS, et al. Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. Arthritis Rheum 2013; 65: S1015.
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151-2168.
https://doi.org/10.1016/S0140-6736(21)00588-2 DOI: https://doi.org/10.1016/S0140-6736(21)00588-2
Rinvoq® (upadacitinib). Prescribing information. AbbVie, Inc., October 2022 [cited February 1, 2023]. Available from: https://www.rxabbvie.com/pdf/rinvoq_pi.pdf.
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol 2022; 158: 404-413.
https://doi.org/10.1001/jamadermatol.2022.0029 DOI: https://doi.org/10.1001/jamadermatol.2022.0029
Silverberg JI, Simpson EL, Calimlim BM, Litcher-Kelly L, Li X, Sun X, et al. Determining severity strata for three atopic dermatitis patient-reported outcome questionnaires: defining severity score ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS). Dermatol Ther (Heidelb) 2022; 12: 2817-2827.
https://doi.org/10.1007/s13555-022-00836-5 DOI: https://doi.org/10.1007/s13555-022-00836-5
de Bruin-Weller M, Deleuran M, Biedermann T, Bissonnette R, Foley P, Girolomoni G, et al. The treat-to-target project in atopic dermatitis: one year on. Acta Derm Venereol 2023; 103: adv5382.
https://doi.org/10.2340/actadv.v103.5382 DOI: https://doi.org/10.2340/actadv.v103.5382
Yeung J, Gooderham MJ, Hong HC, Lynde C, Prajapati VH, Lansang P, et al. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: a Canadian perspective. J Am Acad Dermatol 2023; 89: 372-375.
https://doi.org/10.1016/j.jaad.2023.01.053 DOI: https://doi.org/10.1016/j.jaad.2023.01.053
de Bruin-Weller M, Weidinger S, Gooderham M, Pink AE, Silverberg JI, DiBonaventura M, et al. Efficacy of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis using treat-to-target goals. Poster presented at: 3rd Annual RAD Virtual Conference; December 11-13, 2021; virtual meeting.
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Shawn G. Kwatra, Marjolein de Bruin-Weller, Jonathan I. Silverberg, Peter Lio, Mette Deleuran, Handan Aydin, Brian M. Calimlim, Michael C. Lane, Yingyi Liu, Sarah Ofori, Stephan Weidinger
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.